This Isn't Experimental: Artemisinin Uses Cancer's Own Iron Against It

A cancer drug designer breaks down how artemisinin destroys tumor cells.
#ferroptosis #artemisinin #chemotherapy

👉 Get your free guide, '10 Things to Elevate Your Chemo Journey'

👉 Want personalized attention to help you along your individual cancer journey? Explore 1:1 sessions with Dr. Chaplin

👉 Want to find out more about Dr. Chaplin's journey of bringing a cancer drug to market? Explore his innovations

--------------------------------------------
Episode Description:

There's a compound you can order on Amazon today for about fifteen dollars.

It has two thousand years of human use behind it. A Nobel Prize was awarded for understanding how it works. And researchers at one of the world's leading cancer institutes spent years mapping exactly what it does inside tumor cells.

In this week's episode, Dr. Jay Chaplin breaks down:

• Why certain cancer cells are uniquely and specifically vulnerable to this compound
• The five distinct mechanisms it uses to attack tumors simultaneously
• Which chemotherapy drugs it dramatically amplifies — and exactly when to take it
• How it interacts with radiation therapy at the cellular level
• The one dosing mistake that turns a powerful tool into a liability

This isn't a supplement tip. It's a mechanistic strategy — and the clinical data behind it is more substantial than most people realize.

--------------------------------------------

Inquiries: 

info@elevatingcancertreatment.com

https://elevatingcancertreatment.com

--------------------------------------------

Disclaimer:
The information provided in this podcast is for educational and informational purposes only, and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have heard or read in this podcast or on this channel.
Reliance on any information provided by Dr. Jay Chaplin or Elevating Cancer Treatment is solely at your own risk. Dr. Jay Chaplin is a scientist and drug developer, not a medical doctor providing patient care. The content presented here reflects general scientific understanding and research, and may not be applicable to your individual health circumstances. Individual medical conditions and treatments vary, and no two situations are exactly alike.
Always consult with your personal healthcare provider before making any decisions about your health or treatment plan.

Transcript

SPEAKER_00 0:00

There is a drug that has been curing malaria for over 2,000 years. It comes from the wormwood plant, and it costs almost nothing. You can buy it on Amazon right now, today, for about $15. And it also kills cancer cells. Not by accident, not as a side effect, by a mechanism so precise, so biologically elegant and redundant that researchers at the German Cancer Research Center spent years studying it and concluded that it deserves comprehensive clinical trials. But here's what makes this really interesting. This drug doesn't work the same way for everyone. It works best when you understand exactly how and when to use it, because there's a version of this story where you take it every single day and it helps your cancer. But it also slowly destroys your red blood cells in the process. That's a bad trade-off. I'm going to give you the full picture today what this drug actually does inside tumor cells, the real clinical data from human trials, which cancer treatments it dramatically amplifies and it does. And how to use it alongside radiation. Finally, the one mistake almost everyone makes with it. Stay with me, this is one of the most interesting and underutilized mechanisms in all of integrative oncology, and most integrative doctors get it completely wrong. Welcome to Elevating Cancer Treatment, where we translate the science that matters into something you can actually use. I'm Dr. Jay Chaplin. I'm a PhD, not an MD, so everything here is education, not medical advice. Your oncologist leads your medical team. That's not my job. I'm your scientific edge. I want to be clear about what makes my perspective different. I don't just teach oncology. I actually design cancer drugs. I've spent 30 plus years inside the molecular machinery of tumor cells. That background changes how I explain things, and it especially changes how I think about a compound like artemisinin, because the mechanism here is genuinely extraordinary and it's easy to oversimplify it in a way that leads to serious mistakes. We are not going to do that today. Quick note: we have a free guide called 10 Things to Elevate Your Chemo Journey. It's in the description down below. Grab it. And if you want to work with me directly on your treatment strategy, that's down there too. Alright, let's start back at the beginning. Before we get into the mechanism, let me put three things in your mind that I'll come back to, I promise. First, I'm going to show you why tumor cells are actually better targets for artemisininin than healthy cells, and why that selectivity is built into the drug's chemistry, and it's in a way that's almost poetic. Second, I'll tell you about the drugs that when given with artemisinin dramatically increase how well it works on cancer while protecting your healthy tissue at the very same time. And third, I'll tell you exactly why I tell my clients not to take this compound every day and what to do instead to get almost all the benefit with none of the downside. So hold on to those. Let's build the foundation. So over 2,000 years ago, Chinese physicians discovered that a bitter herb called Qinghao, sweet wormwood, could break a malarial fever. They didn't know why it worked, they just knew that it did. In the 1970s, a Chinese scientist named Tu Yu Yu isolated the active compound from that plant. She called it artemisinin. In 2015, she won the Nobel Prize in Medicine for that. It is now the foundational drug for treating malaria worldwide. Many of the other drugs are based on its molecular structure. Over time, researchers noticed something really unexpected. The same mechanism that allows artemisinin to kill malaria parasites inside red blood cells also kills cancer cells. Specifically and selectively. Here's why, and this is the part I really want you to understand, because it's the key to everything else. Inside every cell, iron plays a critical role in metabolism. But cancer cells are extraordinarily greedy for iron. They need it to fuel their rapid growth, their rapid division. So they upregulate the proteins that import iron. They actively pull iron in from the surrounding environment, and they do it far more aggressively than normal healthy cells do. This is not a flaw, this is a feature of cancer biology. Tumor cells are iron hungry, and artemisinin exploits that hunger perfectly. Artemisenin contains what chemists call an endoperoxide bridge, essentially a molecular tension point. On its own, it's perfectly stable. That's why you can buy it in a pill bottle off of Amazon. But the moment it encounters free iron in a high iron environment, like the inside of a cancer cell, that bridge snaps open. What gets released is a very reactive molecule and not a gentle one. This is what chemists call a highly reactive alkylating radical, and it tears through proteins and DNA alike. It does it completely indiscriminately. It damages everything around it. The cancer cell's own iron addiction has just turned the drug into a targeted weapon inside of tumors. Normal cells, with their much lower iron content, experience far less of this chemistry, far less of this damage. And if they are damaged, they will pause and they will heal the damage. That's what they do. They've got good regulation. Tumors, loaded with iron, bear the brunt, take a lot of damage, and they don't know how to stop multiplying. They keep trying to multiply, often leading to their death because they're multiplying while they're damaged. That's the core mechanism. Iron-activated, free radical mediated DNA damage, and it is well established in the published literature going back to the early 2000s, especially again from researchers at the German Cancer Research Center who spent decades mapping exactly which tumor cell genes confer sensitivity or resistance to artemisinin. But here's where it gets even more interesting, because scientists found that artemisinin doesn't just damage DNA through one pathway, it's actually operating through several distinct mechanisms simultaneously. And one of them is a form of cell death that the cancer world has only recently started to recognize and understand. Research published in the journal Molecules back in 2024, and in a comprehensive review in Seminars in Cancer Biology by Thomas Efferth, one of the leading researchers in this area, laid out the full picture of how artemisinin-type drugs affect cancer cells. It works through at least five distinct mechanisms. Five, believe it or not. One, direct DNA damage, that free radical chemistry we just talked about. Direct iron-catalyzed molecular destruction of DNA inside of cancer cells. We know that happens, that's the primary mechanism. Two, ferrosis. So this is the new one that's gotten a lot of scientific attention. Ferrosis is a distinct form of programmed cell death, different from aptosis. That's driven by iron overload and lipid peroxidation. It takes fatty acids, parts of the membranes, and turns them into soap. Artemisen and its derivatives, particularly dihydroartimizanin, are powerful fertosis inducers. And here's why that matters. Many cancer cells have mutations that have made them resistant to standard aptosis and the drugs that induce it. But they are still vulnerable to ferrosis. Different pathway, same result. Number three, inhibition of angiogenesis. Tumors can't grow without building new blood supply. Artemisenin directly suppresses VEGF, vascular endothelial growth factor. That's one of the key signaling proteins that drives new blood vessel formation to tumors. You can cut off the supply lines. Number four, immune system restoration. This one really excites me when I look at the data. Colorectal cancer research published in the International Immunopharmacology Journal showed that artesuate, an artemisinin derivative, actually reduces the immunosuppressive signals that tumors use to hide from immune cells, specifically TGF beta 1 and IL-10, two of the major ways tumors shut down NK cells and T cells. Artesuate reversed that suppression in vitro. This is a really meaningful finding for anyone who is trying to support immune function, especially the classically cold tumors like osteosarcomas or glioblastomas, because artemisinin also crosses the blood-brain barrier. 5. Multidrug resistance bypass. Here's another exciting result from those German Cancer Research Center publications. Cancer cell lines that had developed resistance to all of the standard chemotherapy drugs by overexpressing genes like MDR1, MRP1, and BRCP, those were not cross-resistant to artesuate. The drug bypasses the standard resistance mechanisms. That's really rare. This is a great fallback. Five mechanisms, all of them pointed at the things that make cancer cells hard to kill. So all that sounds great, but what does this actually look like in human beings and in actual clinical trials? Because I know that's the question you're sitting with right now. It's what I talk about, it's what you're expecting. Mechanism is great, human clinical data is better. I'm going to be straight with you about where the clinical data stands because this is where I think a lot of the online conversation about artemisen goes completely off the rails. People either overclaim it as a cure or dismiss it because the human trial data is still early. The truth is a lot more nuanced and much more interesting. The most important phase one trial of IV artesuate in cancer was published in Cancer Chemotherapy and Pharmacology back in 2018 by researchers at Georgetown and Innova Health. They enrolled 19 patients, just 19, tiny, but they were with advanced solid tumors. It was a tiny study, but with heavily pretreated patients who had already been through multiple lines of therapy. They used IVR tesuate at escalating doses. The maximum tolerated dose was determined to be 18 mg per kilogram. No objective tumor responses by the resist criteria. But, and this matters, four patients had stable disease, including three with prolonged stable disease lasting 8, 10, and 11 cycles. That's a disease control rate of 27% in people whose cancers had already resisted everything else. In a heavily pretreated population with no other options, holding a cancer stable for 11 cycles is not nothing. So the honest summary: as a monotherapy, artemisinin and artesuate produce modest effects. Roughly an 8-12% rate of measurable tumor shrinkage across the literature, with better results for disease stabilization. But again, disease stabilization is probably not what you're looking for. So that's meaningful for a natural compound you can buy from Amazon and with a very good safety profile. But it's not a home run, at least not by itself. Where the data get much more exciting is in combination, and that's what I want to talk about next. Because it turns out artemisinin alone is like a spark plug without an engine. But you combine it with the right partners and something very different starts happening. The combination of dihydroartemisinin, or DHA, artemisinin's active metabolite, with platinum drugs has now been studied in multiple preclinical models with genuinely striking results, consistently across the board. A 2021 study in cell death and disease tested DHA plus cisplatin in pancreatic ductal adenocarcinoma, one of the most treatment-resistant cancers that we know of. The combination worked synergistically. It inhibited tumor cell proliferation more than either drug alone. It caused significantly more DNA damage, and critically, it triggered ferrotic cell death through iron dysregulation. The researchers found that adding iron to the system accelerated the ferrotic killing even further. The tumor's own iron addiction was weaponized against it. This is also very easy to engineer through diet as well, and it's something we regularly coach our clients on, especially when they will be using artemisinin. Similarly, a 2024 study in cancer medicine also confirmed this in lung cancer. DHA plus cisplatin produced far superior outcomes by upregulating a protein called Zip14 that drives iron into cancer cells. This maps directly to what I recommend to our clients. If you are on a platinum chemotherapy regimen, cisplatin, carboplatin, or oxaliplatin, adding artemisinin or artesuate the day before an infusion, the day of an infusion, and the day after an infusion is a strategically sound approach. You are hitting the DNA damage pathway from two different angles simultaneously. The cancer cell gets attacked through the platinum's cross-linking mechanism and through the artemisininin-driven ferrotic mechanism, both at the same time. Different tools, same target, dramatically more pressure. This principle also extends to many other DNA damaging chemotherapies as well: 5-fluor uracil, arinatecan, temazolamide, cape cytobine. These all damage DNA through their own mechanisms. And artemizanin adds a parallel iron-driven damage pathway on top of that. Again, this is synergy, not just additive effects. The radiation story is particularly fascinating and supported by good mechanistic evidence in the published literature. Research from the National Cancer Center of South Korea, published in the Journal of Cancer Research and Clinical Oncology, tested dihydroartemin combined with radiation in glioma cells. Their results showed that DHA significantly increased radiosensitivity, and they found the mechanism. DHA generates reactive oxygen species and simultaneously suppresses glutathione S. transferase. That's an enzyme that cancer cells use to mop up radiation-induced free radicals. When you both block that cleanup mechanism and simultaneously add more free radicals, the cancer cell's ability to survive radiation damage just collapses. A separate study in cervical cancer model systems showed that DHA eliminates the G2M cell cycle checkpoint, essentially preventing cancer cells from pausing to repair radiation damage before dividing. The cell gets pushed right into replication even while the DNA is still broken. That is a lethal outcome for the tumor cell. And this is where iron loading becomes a complete strategy that I use with my clients who are going into radiation treatment. It both sensitizes the tumors to radiation by itself and it allows for better artemisininin activity. You are amplifying two independent approaches that then both amplify each other even more. This is not something most radiation oncologists will tell you, because it's not their department, and they are appropriately cautious about anything they haven't personally verified. These compounds don't interact negatively with radiation itself, and they don't interfere with standard radiation protocols. You can safely use them during radiation treatment, and they make it better, never worse. So if artemisenin is so great, why don't we recommend it all the time for everyone? I really want to talk about the limitation because this is the thing that almost everyone gets wrong, and it's serious enough that I need you to really hear it. Artemisen works in high iron environments. Cancer cells are the primary target because they are loaded with iron. But red blood cells also contain iron. That's why it works for malaria. There's quite a lot of iron in red blood cells, that's how they carry oxygen. Taken chronically at meaningful doses, artemisinin will damage red blood cells. It's not a matter of if, it's a matter of how much and how fast. It will cause hemolysis, the breakdown of red cells, and over time that leads to severe anemia. This is not theoretical. The clinical trial data showed it. My clients who have come to me already taking artemisinin daily from many integrative oncologists, many of them were showing progressive drops in their hemoglobin and red cell counts. The compound that was supposed to help them fight their cancer was quietly depleting one of their body's most critical resources. The solution to this is pulsed dosing at the times with the highest leverage. For patients who are not on active chemotherapy or radiation, such as someone in a surveillance phase after treatment, someone who's trying to prevent recurrence or with very slowly progressing disease and you're trying to tip the balance, doing a three-day pulse once per month is a well-tolerated and sensible approach. Three days on and then a month off. That keeps the pressure on the cancer without giving the cumulative iron depletion enough time to build and become serious. For patients actively on DNA damaging chemotherapy or radiation, the window approach I described, a day before, the day of, and the day after infusion or radiation treatment, is actually ideal because you naturally have these long gaps between treatments where your red cell system has a chance to recover. And critically, if you are already anemic from chemotherapy or your red cell counts are dropping and heading toward that threshold, artemisinin should be avoided until that resolves. Do not add another iron depleting agent on top of a bone marrow that's already under stress. Please, track your complete blood count, watch your hemoglobin and red cell count. That's the canary in the coal mine. One more thing I want to address because it comes up constantly in my consultations. Artemisenin in a standard oral capsule is reasonably bioavailable. It works. But the key word here is reasonably. Most of the trials that produced positive results used either IV administration or specialized oral delivery systems. These are formulations designed to maximize absorption. If you're buying standard artemisinin capsules, opening them up and mixing them with food does not meaningfully improve absorption. The capsule doesn't change anything. That won't hurt, but it's not the delivery optimization you need. What does help? Taking it with a small amount of fat, since artemisin in itself is lipophilic. It dissolves in the fat and the fat carries it across your intestines into your bloodstream. Now, artesuate is a water-soluble derivative that has better absorption characteristics than the parent compound. If you have access to it through integrative oncologists, artesuate is usually given in IVs, and it's a known easy, straightforward way to get this. The question is, can you convince them to give it to you on a cycle that matters and is good rather than consistent and damaging? The practical bottom line for most people is that standard oral artemisinin at 200 milligrams, taken in the pulsed protocol I described, along with fat, is accessible and clinically reasonable. Here's what I want you to take from everything we've covered today. Artemisen is not a cure. It's an amplifier. It is a compound that looks at the biology that makes cancer cells tick, their iron hunger, their lack of DNA repair mechanisms, and their inability to quit dividing to repair themselves, and uses those very features as the focus for attack. That's not magic, that's mechanistic elegance. The reason most oncologists don't bring it up isn't that they think it doesn't work. It's that they don't have a trial large enough to prescribe from. The oncology system requires a large phase three trial result with a big survival difference to change practice. Artemizanin has phase one and two data. It has preclinical data and decades of safety data in humans from malaria treatment. That's meaningful, but it's not enough for a standard of care recommendation. But it is more than enough to inform a thoughtful individualized strategy based on excellent synergy with standard of care treatments, particularly the platinum class drugs and radiation. The patients I work with who use artemisen as a part of a broader, well-designed plan, alongside their chemotherapy, not replacing it, alongside it, and timed with their radiation, pulsed to protect their bone marrow, these people are not replacing standard treatment. They're adding a biologically grounded multiplier of pressure that their cancer didn't expect and can't adjust to. That's our goal. Strategy over random grab bag supplementation. If you want to think through whether artemisinin makes sense for your specific situation, your cancer type, your treatment protocol, your blood counts, and your genomic profile, that's exactly the kind of individualized analysis I do in my consulting work. The link to work with me directly is down in the description below, and I'd genuinely love to help. At the beginning of this video, I told you there was a 2,000-year-old compound that kills cancer cells through a mechanism so precise it won a Nobel Prize. And there was a version of the story where taking it every day actually hurts you more than it hurts the cancer. Now you know both versions. You know the mechanism. You know the clinical data. You know how to time it with chemotherapy or with radiation. You know how to stack it and get the best possible value. And you know how to protect yourself from the one real downside, severe anemia. That's not a supplement stack, that's not a supplement grab bag. That is a clear strategy. If this was useful, please hit like, subscribe, and share this with someone in your life who's navigating cancer treatment right now. And please leave me a comment. Had you heard of artemisen before this? Did your oncologist ever bring this up? You can make thoughtful, biologically grounded decisions. That's what this channel is for, to help you do that. That's your best leverage.